• CVS

Deutsche Bank upgrades CVS with recovery on sight

Deutsche Bank upgrades CVS Health to 'buy', citing potential earnings turnaround and leadership changes, expecting significant stock price growth over the next two years despite regulatory risks.

• CVS

CVS Health plans bond sale and $3 billion debt buyback- report

• BA
• CMG
• CVS
• DAL
• HTZ
• INTC
• NEST
• NKE
• SBUX

Factbox-From Boeing to Intel: CEO exits at major global companies in 2024

• CVS
• F
• NVDA
• SAVE
• SMCI
• SNDX
• TSLA

Tesla, Spirit Airlines and CVS Health rise premarket; Nvidia falls

US stock futures are mixed as Tesla and Syndax Pharmaceuticals rise, while Nvidia dips. Traders are focused on upcoming earnings and Fed speeches.

• CVS

CVS jumps on report it will add to board in deal with hedge fund Glenview

CVS Health will expand its board by adding four members, including Glenview Capital's CEO, in response to investor pressure after a significant stock price decline.

• CVS

CVS adds four new board members in deal with Glenview Capital

CVS Health appointed four new board members, including Glenview Capital's CEO, amid pressure to improve operations and shareholder value while facing rising medical costs.

• CVS

Glenview, Sachem Head, Third Point buy CVS shares during Q3-filings

Three investment firms increased their stakes in CVS Health, signaling potential changes. New CEO David Joyner replaces Karen Lynch amid stock price decline and investor unrest.

• CVS

Earnings call: CVS Health reports mixed Q3 results, outlines future plans

• CVS

CVS Health Corp earnings missed by $0.46, revenue topped estimates

CVS Health Corp reported Q3 EPS of $1.09, missing estimates. Revenue was $95.4B. Stock down 21.22% in a year, with 15 negative EPS revisions recently.

• CNC
• CVS
• HUM

Wall Street looking for CVS to show execution plan

CVS Health's new CEO, David Joyner, faces challenges in managing rising patient costs in Medicare, addressing disappointing earnings, and improving shareholder value amid significant company restructuring.